

Rome, 13/10/2025

Prot. n. 454/DG

**BAMBINO GESÙ CHILDREN'S HOSPITAL
THE GENERAL DIRECTOR**

HAVING SEEN Legislative Decree No. 36 of 31 March 2023 and subsequent amendments (hereinafter the “Public Contracts Code”), as amended;

HAVING SEEN the Presidential Decree of 5 October 2010, no. 207, as currently in force, which regulates the execution and implementation of the Public Contracts Code;

HAVING SEEN the contracting decision no. 126 prot. no. 332/DG of 02/09/2025, the preamble of which is hereby deemed to be fully incorporated, with which the General Director of the Bambino Gesù Pediatric Hospital (“OPBG”) authorized the initiation of the procedure through direct award pursuant to art. 50, paragraph 1, letter b), of Legislative Decree 36/2023 for the provision of the Cell Line Characterization Service, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the release of a 3T3 mouse embryonic fibroblast cell bank to be used as a feeder layer in the production of a gene therapy product indicated for the treatment of patients affected by recessive dystrophic epidermolysis bullosa caused by loss-of-function mutations of the COL7A1 gene, which encodes type VII collagen, i.e. the constituent of the anchoring fibrils that ensure dermo-epidermal adhesion for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital, as part of the Project “Hub Life Science - Advanced Therapy (LSH-TA) PNC-E3-2022-23683269 - Funded by the Ministry of Health as part of the National Complementary Plan “Innovative Health Ecosystem” coordinated by Professor Franco Locatelli. The above-mentioned service is provided by BioReliance Ltd for an amount equal to Euro 60,882.65 (sixty thousand eight hundred and eighty-two/65) plus VAT, where applicable, as reported in the Contracting Decision, simultaneously appointing Professor Concetta Quintarelli as the Sole Project Manager, pursuant to Article 15 of the Public Contracts Code;

HAVING SEEN the transmission on 22/09/2025 by the OPBG to the economic operator BioReliance Ltd of the invitation letter with the related attachments, indicating 12:00 on 30/09/2025 as the deadline for participation in the tender procedure in question;

HAVING SEEN the response to the invitation letter sent by BioReliance Ltd acquired in the OPBG records on 09/22/2025, accompanied by all the required documentation digitally signed;

HAVING SEEN the evaluation document dated 01/10/2025 with which the proposed technical offer was examined;

HAVING SEEN the evaluation document dated 01/10/2025, with which the economic offer was assessed as appropriate for the amount of Euro 60,882.65 (sixty thousand eight hundred and eighty-two/65) plus VAT, where applicable, as reported in the Contract Determination;

WHEREAS the OPBG has initiated the verification of the prescribed requirements in relation to BioReliance Ltd;

CONSIDERING that it is necessary to proceed with the awarding of the above-mentioned tender on the basis of the documents and documentation produced, necessary for the stipulation of the contract;

CONSIDERING that, as provided for by Article 17, paragraph 5 of the Public Contracts Code, the award becomes effective after positive verification of the possession of the required requirements, as well as the establishment of the definitive guarantee referred to in Article 9 of the Specifications;

HAVING SEEN the CUP E83C22006230001 assigned by the Ministry of Health.

All of the above having been seen, considered and stated, which constitutes an integral part of this provision

ARRANGE

1. to award to the company **BioReliance Ltd** with registered office in Glasgow, Scotland, at Unit 5, Todd Campus, West of Scotland Science Park, G20 0XA, Tax

- Code 6805014990 / VAT number GB 845 3370 24, the procedure through direct award pursuant to art. 50, paragraph 1, letter b), of Legislative Decree 36/2023 for the provision of the Cell Line Characterization Service, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the release of a 3T3 mouse embryonic fibroblast cell bank to be used as a feeder layer in the production of a gene therapy product indicated for the treatment of patients affected by recessive dystrophic epidermolysis bullosa caused by loss-of-function mutations of the COL7A1 gene, which encodes type VII collagen, i.e. the constituent of the anchoring fibrils that ensure dermo-epidermal adhesion for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital, as part of the Project "Hub Life Science - Advanced Therapy (LSH-TA) PNC-E3-2022-23683269 - Funded by the Ministry of Health as part of the National Complementary Plan "Innovative Health Ecosystem" coordinated by Professor Franco Locatelli. The above-mentioned service is provided by BioReliance Ltd for an amount equal to Euro 60,882.65 (sixty thousand eight hundred and eighty-two/65) plus VAT, where applicable, as reported in the Contract Determination;
2. that the aforementioned award becomes effective only following the activation of the definitive guarantee constituted by BioReliance Ltd, pursuant to art. 117 of Legislative Decree 36/2023, in the forms provided for by art. 106 of Legislative Decree 36/2023, as provided for in art. 9 of the Specifications, within 10 days of the signing of this award decree;
 3. that the aforementioned award becomes effective only following the positive outcome of the checks required by the legislation in force on the participation requirements;
 4. which, following the checks foreseen in points 2 and 3, will be followed by the necessary formalisation of the contract;
 5. to advertise the award using the methods provided by law.

The General Director
Antonio Perno